fashion -WSS

fashion

author：comprehensive 2025-10-02 18:06:14 - browse：88

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Diverse clinical trials: Why aren’t we there yet?

entertainment

WSS

Physicians aren't 'burning out.' They're suffering from moral injury

How medical schools plan to diversify without affirmative action

What to make of Biden’s latest efforts on cancer research

How to ethically and practically extend health care to all

FDA panel endorses Alnylam’s heart drug — after picking it apart

FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

fashion

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Florida officials tell state schools to teach AP Psychology 'in its entirety'

After affirmative action ruling, medical educators look to 'holistic review'

FDA panel endorses Alnylam’s heart drug — after picking it apart

After affirmative action ruling, medical educators look to 'holistic review'

Food makers to regulators: Ultra

Malaria cases in Florida and Texas: Here’s what you need to know

The a glaring gap in research on serious mental illness and primary care

Bright Health sells Medicare Advantage business to Molina

Food makers to regulators: Ultra

explore

FDA approves updated Covid vaccines

H.R. 3 is the wrong path to lower drug costs

Popular nasal decongestant doesn't actually relieve congestion

FDA scientists endorse Pfizer/BioNTech Covid

Telehealth for opioid use disorder is lifesaving

What to make of Biden’s latest efforts on cancer research

Wikipedia

entertainment

focus

focus